

13th ADVANCED COURSE OF VACCINOLOGY- 2012

13th ADVANCED COURSE OF VACCINOLOGY- 2012

MONDAY 14 MAY 2012		Theme Coordinator : Adam Finn (Bristol, UK)
09 :00	Opening	Alain Mérieux , President, Fondation Mérieux
09 :15	Definition of the course objectives	Paul-Henri Lambert , Director of the ADVAC Course
SESSION 1.- THE MULTIFACETED NATURE OF VACCINOLOGY		Chairpersons: Marie-Paule Kiény (WHO) and Claire-Anne Siegrist
09:40-10:20	Opening Lecture: The history of vaccinology and the present vaccine pipe line	Stanley Plotkin , University of Pennsylvania
10:20-10:40	Discussion	
10:40-11:10	Break	
11:10-11:55	Impact of vaccination on disease epidemiology	Roy Anderson , Imperial College, London, UK
11:55-12:20	Discussion	
12:30-14:00	Lunch	
14:00-14:30	The challenge of malaria vaccines-	Vasee Moorthy , WHO
14:30-14:50	Discussion	
14.50-15.20	Essential practical aspects in conducting phase III trials	Hanna Nohynek , THL, Helsinki
15:20-15:40	discussion	
15:40-16:00	Break	
16:00-16:40	Keynote lecture: Access to cost-effective vaccination at global level	Seth Berkley , GAVI Alliance
16:40-17:00	discussion	

TUESDAY 15 MAY 2012		Theme Coordinator : Adam Finn (Bristol, UK)
SESSION 2 - HOW VACCINES WORK		Chairpersons: Adam Finn and Daniel Pinschewer (UNIGE)
09:00-09:30	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses a- B-cell responses	Claire-Anne Siegrist , University of Geneva
09:30-10:00	Discussion	
10:00-10:30	<u>Break</u>	
10:30-11:00	What a vaccinologist should know about the basic aspects of immunological responses b- T-cell responses	Claire-Anne Siegrist , University of Geneva
11:00-11:30	Discussion	
11:30-12:20	Use and limitations of correlates of immunity in vaccinology:	Stanley Plotkin and Andrew Pollard , University of Oxford
12:20-12:50	Common discussion	
	<u>Lunch</u>	
14:15-14:45	Immunological basis for responses to mucosal vaccines	Adam Finn , University of Bristol
14:45-15:05	Discussion	
15:05-16:00	Vaccines and Immunological memory Quiz and general discussion	Claire-Anne Siegrist , University of Geneva
16:30-17:10	Special lecture: Vaccine-induced Immunological memory	Rafi Ahmed , Emory University
17:10-17:30	Discussion	
17:45	Debate with drinks on a hot topic : narcolepsy?	Chair Adam Finn with Hanna Nohynek

WEDNESDAY 16 MAY 2012		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	SESSION 3 – DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT	Chairpersons: Luc Hessel & Georges Thiry
09:00-09:30	How do vaccines cause adverse events ?	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:30-09:50	Discussion	
09:50-10:20	Vaccine adjuvants	Martin Friede , WHO, Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	From pre-clinical research to vaccine development: Examples of go-no-go decisions	Georges Thiry , PATH
11:30-11:50	Discussion	
11:50-12:20	Advances in vaccine and immunization technologies	Carole Heilman , NIAID
12:20-12:40	Discussion	
	Lunch	
14:00-14:30	Special lectures: New vaccines in development (1) HIV vaccines	Brigitte Autran , INSERM, France
14:30-14:50	Discussion	
15:00-17:00	Regulatory considerations e.g. re:new adjuvants Round table debate	Norman Baylor (BCG), Pieter Neels (Federal Agency for Medicinal and Health Products Brussels & CHMP-EMA) – Nathalie Garçon , GSKBio and Michael Decker (Sanofi Aventis,)
17:00-17:30	Lessons from pitfalls experienced in clinical trials and in the registration process	Luc Hessel , Sanofi Pasteur MSD, Lyon,
17:30-17:50	Discussion	

	THURSDAY 17 MAY 2012	Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)	Chairpersons: Hanna Nohynek
09:00-09:40	Clinical trials: an overview of issues to be considered	Myron Levine , University of Maryland, Baltimore, USA
09:40-10 :00	Discussion	
10:00-10:30	Introduction to statistical aspects of clinical trials 1- Defining sample size: practical approaches and examples	Peter Smith , LSTMH, UK
10:30:10:50	Discussion	
10:50-11:00	<u>Break</u>	
11:00-13:45 <i>12:40-13:10 lunch buffet</i>	How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise: How to design a phase II trial - Group 1: Adam Finn Group 2: Edwin Asturias Group 3: Hanna Nohynek Group 4: George Thiry Group 5: Luc Hessel Group 6: Kari Johanssen	
13.50-14.20	Public and media perception of vaccination	David Salisbury , Department of Health, UK,
14:20-14:40	Discussion	
14:40-15:15	Special lectures: New vaccines in development (2) The challenge of developing new tuberculosis vaccines	
15:15-15:35	Discussion	David Lewis , Uni Surrey UK
15:35-15:55	<u>Break</u>	
15:55-16:25	Clinical trials: role of a DSMB- (with several examples of intervention)	Penny Heaton , Novartis Vaccines & Diagnosis

16:25-16:40	Discussion	
16:40-17:10	Assessing herd protection	John Clemens , UCLA, Los Angeles
17:10-17:30	Discussion	

	FRIDAY 18 MAY 2012	Theme Coordinator : Neal Halsey (Baltimore)
	SESSION 5– VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS	Chairpersons: Kari Johanssen and Neal Halsey
08:45-09:15	Lessons from previous adverse effects of vaccination and Assessment of causal relationships	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:15-09:35	Discussion	
09:35-10:05	Immunological safety of vaccination (Autoimmune and allergic diseases)	Paul-Henri Lambert , Dir ADVAC
10:05-10:25	Discussion	
10:25-10:40	Break	
10:40-11:10	Population-based post-licensure surveillance	Steve Black , Cincinnati Children's Hospital Medical Center
11:10-11:40	Immunization safety in developing country vaccination programs	Philippe Duclos , WHO
11:40-12:20	Common Discussion	
	<u>Lunch</u>	
13:30-14:00	Risk communication: An overview	Noni McDonald , Dalhousie Univ, Halifax Canada

14:00-14:20	Discussion	
	SESSION 6– ASSESSING VACCINES IN CLINICAL TRIALS (II)	Chairperson: Hanna Nohynek
14:20-14:50	Introduction to statistical aspects of clinical trials- 2- Statistical assessment of phase 3 trials- 30 min	Peter Smith , LSTMH, UK
14:50-15:10	Discussion	
15:15-18:00	Small group exercise 2: Designing and analysing the results of 3 selected phase III trial (pneumococcal conjugate vaccine in The Gambia, among Navajo Indians in the U.S. and in South Africa)	Objective: To understand how to critically appraise and compare phase III trial results
	Introduction to the group work Exercise:	Hanna Nohynek
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Hanna Nohynek Group 3: - Facilitator: Steve Black Group 4: - Facilitator: Kate O'Brien Group 5: - Facilitator: Peter Smith Group 6: - Facilitator: Kari Johanssen	

	SATURDAY 19 MAY 2012	Theme Coordinator : Edwin Asturias (Guatemala City)
	SESSION 7- ETHICAL ISSUES Ethical issues related to clinical trials – Revisiting the Helsinki Declaration	Chairpersons: Kari Johanssen
08:45-09:45	Clinical trials: Ethical issues basic principles & practical approaches Specific issues in developing countries	Catherine Slack (University of KwaZulu-Natal, South Africa) Vasee Moorthy , WHO
09:45-10:15	Common discussion	
10:15-12:45	Small group exercise 3: Ethical issues –topics to be selected with facilitators	Coordinated by Kari Johanssen & Betty Dodet (Lyon)
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Catherine Slack Group 3: - Facilitator: Noni McDonald Group 4: - Facilitator: Betty Dodet Group 5: - Facilitator: Kari Johanssen Group 6: - Facilitator: Vaseeharan Sathiyamoorthy	

	MONDAY 21 MAY 2012	Theme Coordinator : Mark Miller (Bethesda)
08:40-09:00	Review and conclusions of the 19 May Ethics session	Cathy Slack
	SESSION 8.1- INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES Approaches to help the decision-making process Case Case # 1 - Pneumococcal and Influenza vaccines in infants and adults	Chairperson: Marie-Paule Kieny , WHO and Juhani Eskola , THL, Finland
09:00-09:35	Pneumococcal conjugate vaccines: overview-	Ron Dagan , Soroka Medical Center, Beer Sheva
09:35-10:10	Pneumococcal vaccines: role of viral infections, ecological aspects, and issues related to adult vaccination	Keith Klugman Emory Univ
10:10-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	Understanding vaccine responses in the elderly	Richard Aspinall , Cranfield University, UK
11:30-11:50	Discussion	
11:50-12:20	Understanding responses to polysaccharide and conjugate vaccines in infants and adults	David Goldblatt , Institute of Child Health, London
12:20-12:40	Discussion	
12:40-14:00	<u>Lunch</u>	
14:00-14:40	Influenza biology , new vaccines and vaccination strategies for different age groups	Kathy Neuzil , PATH, Seattle
14:40-15:00	Discussion	
15:00-15:30	Success and challenges with Rotavirus vaccines:	Umesh Parashar CDC
15:30-15:50	Discussion	
15:50-16:10	Break	
16:10-16:50	Special lectures: The population biology of bacterial pathogens and its importance for vaccination strategies	Richard Moxon , Oxford University
17:30	Debate with drinks on hot topic e.g. adult vaccination	

	TUESDAY 22 MAY 2012	Theme Coordinator : Mark Miller (Bethesda)
	SESSION 8.2 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (2)	Chairperson: Bernard Fritzell , Lyon and Alan Shaw, Vaxinnate
	Case-specific study #2: Meningococcal vaccines	
09:00-09:30	Approaches towards new Meningococcal vaccines	Giuseppe Del Giudice, Novartis Vaccines
09:30-09:50	Discussion	
09:50-10:20	The MenA-conjugate experience	Brian Greenwood, UK
10:20-10:40	Discussion	
10:40-11:00	<u>Break</u>	
	Decision-making process for the use of new vaccines at national or regional level	
11:00-11:30	Role of disease burden assessment in the decision-making process	Brad Gessner, Association pour la Médecine Préventive, AMP
11:30-11:50	Discussion	
11:50-12:20	Health economics as a tool in analyzing Vaccine Policy Options	Mark Miller, Fogarty International Center
12:20-12:40	Discussion	
12:40-13:40	Lunch buffet	
13:40-14:10	Challenges and solutions in making evidence-based national vaccination policies and recommendations	Kamel Senouci, SIVAC
14:10-14:30	Discussion	

14:30-17:30	Small group exercise 4: Decision-making for the evaluation and impact of new vaccines introduced in selected countries: safety and effectiveness	organized by Kari Johanssen, ECDC and Hanna Nohynek
	Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome Group 1 Rota Kamel Senouci and Mark Miller Group 2 Rota XXXX Group 3 HPV Alan Shawn and Hanna Nohynek Group 4 HPV Edwin Asturias and Kari Johanssen Group 5 Influenza Brad Gessner Group 6 PCV Brian Greenwood	
17:40	Soccer game North vs South of the World	

	WEDNESDAY 23 MAY 2012	Theme Coordinator : Neal Halsey (Baltimore)
	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES	Chairpersons: Janet Englund and Rana Hajjeh
	1. Vaccination and pregnancy	
09:00-09:30	Main issues and applications in developed and developing countries	Janet Englund , Children's Hospital and Regional Medical Center, Seattle
09:30-09:50	Discussion	
	2. Vaccination in early life	
09:50-10:20	Advantages and limitations	Claire-Anne Siegrist , University of Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
	3. Vaccination schedules	
11:00-11:30	Past, present and future – Is there some rationale?	Edwin Asturias

11:30-11:50	Discussion	
11:50-14:30	Parallel working group sessions (with sandwich lunch)	
	1. Capacity Building in Developing Countries -	Charles Mgone (Executive Director EDCTP) Arnd Hoeveler , EC, Brussels, and Alan Shaw , Vaxinnate
	2.National decision making for immunization programmes	Allison Mawle , CDC, and Philippe Duclos ,WHO
	3.Clinical vaccinology : patients' problem solving	CA Siegrist and Alessandro Diana
	4. new approaches towards vaccination e-registries	Kari Johanssen (ECDC) and Rana Hajeh (CDC)
14:30-15:00	Info on main ADVAC sponsors activities- Grant opportunities in vaccinology: The EC programmes	Arnd Hoeveler , Head, Health and Biotechnology, EC, Brussels and Charles Mgone , Executive Director EDCTP
15:00-15:20	Discussion	
15:20-15:40	Break	
	Special lectures: New vaccines	
15:40-16:10	Prospects for dengue and JE vaccines	Hal Margolis , CDC
16:10-16:30	Discussion	
16:30-17:10	THE PLOTKIN LECTURE: The past as prologue	Stanley Plotkin , University of Pennsylvania
17:10-17:40	discussion	
18:00	Departure to Château de Menthon visit and special reception -	

THURSDAY 24 MAY 2012		Theme Coordinator : Edwin Asturias (Guatemala City)
		Chairperson: Edwin Asturias
09:00-09:40	Vaccination in immune-compromised individuals, including HIV positive patients	Claire-Anne Siegrist, University of Geneva
09:40-10:00	discussion	
	<u>Special lectures: New vaccines</u>	
10:00-10:30	CMV vaccines in development	Stanley Plotkin
10:30-10:50	Discussion	
	Break	
11:10-11:40	HPV vaccines	Xavier Bosch, Catalan Institute of Oncology
11:40-12:00	Discussion	
12:00-12:30	Challenges for making vaccines : essential steps	James Robinson, Merck
12:30-12:50	Discussion	
12:50-13:45	<u>Buffet Lunch</u>	
13:45-14:15	Role of DC vaccine Industry for meeting the Global needs	Suresh Jadhav, Serum Institute of India, Chair DCVMN (30 min)
14:15-14:35	Discussion	
	Elimination or Eradication strategies?	
14:35-15:35	Polio, Measles and rubella	Roland Sutter WHO – 30 min Peter Strebel, WHO- 30 min TBC
15:35-16:15	General discussion coordinated by	Stanley Plotkin-
16:15	<u>Presentations by participants and poster discussion</u> Brief presentations by participants and poster discussio	

	FRIDAY 25 MAY 2012	Thematic supervisor : Edwin Asturias (Guatemala City)
	SESSION 10: FACING THE MEDIA	Chairperson: Edwin Asturias
09:00-12:30	Interactive session	Deborah Hall , Broadcaster and media affairs consultant, London,
	Introduction to media dynamics: How to best deliver vaccinology r elated messages to different interest groups Lunch	(organized by Edwin Asturias)
14:00-15:00	CME credits Diploma ceremony – Distribution of CD Roms with course slides	Stanley Plotkin and Paul Henri Lambert
15:00	Closure of the Course The educational quality of the course will be certified by Prof. Claire-Anne Siegrist and Dr Hanna Nohynek (CME related issues)	

14th ADVANCED COURSE OF VACCINOLOGY- 2013

MONDAY 6 MAY 2013		Theme Coordinator : Adam Finn (Bristol, UK)
09 :00	Opening	Alain Mérieux, President, Fondation Mérieux
09 :15	Definition of the course objectives	Paul-Henri Lambert, Director of the ADVAC Course
SESSION 1.- THE MULTIFACETED NATURE OF VACCINOLOGY		Chairpersons: Marie-Paule Kieny (WHO) and Claire-Anne Siegrist
09:40-10:25	Opening Lecture: Impact of vaccination on disease epidemiology	Roy Anderson, Imperial College, London, UK
10:25-10:45	Discussion	
10:45-11:15	Break	
11:15-11:55	Access to vaccination in GAVI countries and at global level	Seth Berkley, GAVI Alliance
11:55-12:20	Discussion	
12:30-14:00	<u>Lunch</u>	
14:00-14:30	Public and media perception of vaccination	David Salisbury, UK
14:30-14:50	Discussion	
14.50-15.20	Role of DC vaccine industry for meeting global needs	Suresh Jadhav, Serum Institute of India,
15:20-15:40	discussion	
15:40-16:00	Break	
16:00-16:30	Development and production of vaccines for global use: the role of vaccine industry	Luis Jodar, Pfizer
16:30-17:00	discussion	
17:30-19:30	Self-presentation of individual participants (background, interests in life...) & Welcome reception	

TUESDAY 7 MAY 2013

SESSION 2 - HOW VACCINES WORK		Chairpersons: Adam Finn and Daniel Pinschewer (UNIGE)
09:00-09:30	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses a- B-cell responses	Claire-Anne Siegrist, University of Geneva
09:30-10:00	Discussion	
10:00-10:30	<u>Break</u>	
10:30-11:00	What a vaccinologist should know about the basic aspects of immunological responses b- T-cell responses	Claire-Anne Siegrist, University of Geneva
11:00-11:30	Discussion	
11:30-12:20	Use and limitations of correlates of immunity in vaccinology:	Andrew Pollard, University of Oxford
12:20-12:50	Common discussion	
	<u>Lunch</u>	
14:15-14:45	Immunological basis for responses to mucosal vaccines	Adam Finn, University of Bristol
14:45-15:05	Discussion	
15:05-16:00	Vaccines and Immunological memory Quiz and general discussion	Claire-Anne Siegrist, University of Geneva
16:30-17:10	Special lecture: Vaccine-induced Immunological memory	Rafi Ahmed, Emory University
17:10-17:30	Discussion	
17:45	Debate with drinks on a hot topic	Chair; Adam Finn with Hanna Nohynek

WEDNESDAY 8 MAY 2013		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	SESSION 3 – DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT	Chairpersons: Carole Heilman (NIH)
09:00-09:30	How do vaccines cause adverse events ?	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:30-09:50	Discussion	
09:50-10:20	Vaccine adjuvants	Martin Friede , WHO, Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	From pre-clinical research to vaccine development: Examples of go-no-go decisions	Georges Thiry , PATH
11:30-11:50	Discussion	
11:50-12:20	Advances in vaccine and immunization technologies	Cristina Cassetti , NIAID
12:20-12:40	Discussion	
	Lunch	
14:00-14:30	Special lectures: New vaccines in development (1) HIV vaccines	Brigitte Autran , INSERM, France
14:30-14:50	Discussion	
15:00-17:00	Regulatory considerations e.g. re: hot topic (adjuvants?) Round table debate	Norman Baylor (BCG), Pieter Neels (Federal Agency for Medicinal and Health Products Brussels & CHMP-EMA) – Nora Dellepiane , WHO Ozzie Berger , GSKBio and Michael Decker (Sanofi Pasteur)
17:00-17:30	Lessons from pitfalls experienced in clinical trials and in the registration process	Luc Hessel , Sanofi Pasteur MSD, Lyon,
17:30-17:50	Discussion	

THURSDAY 9 MAY 2013		
	SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)	Chairpersons: Hanna Nohynek
09:00-09:40	Clinical trials: an overview of issues to be considered	Myron Levine , University of Maryland, Baltimore, USA
09:40-10:00	Discussion	
10:00-10:30	Introduction to statistical aspects of clinical trials 1- Defining sample size: practical approaches and examples	Peter Smith , LSTMH, UK
10:30-10:50	Discussion	
10:50-11:00	Break	
11:00-13:45	How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise: Group 1: Adam Finn Group 2: Edwin Asturias Group 3: Hanna Nohynek Group 4: George Thiry Group 5: Luc Hessel Group 6: Kari Johanssen	
<i>12:40-13:10 lunch buffet</i>		
13.50-14.20	Essential practical aspects in conducting phase III trials	Hanna Nohynek , THL, Helsinki
14:20-14:40	Discussion	
14:40-15:15	Special lectures: New vaccines in development (2) Challenges and prospects for new tuberculosis vaccines	David Lewis , Uni Surrey UK
15:15-15:35	Discussion	
15:35-15:55	Break	
15:55-16:25	Clinical trials: role of a DSMB- (with several examples of intervention)	Penny Heaton , Novartis Vaccines & Diagnosis
16:25-16:40	Discussion	
16:40-17:10	Assessing herd protection	John Clemens , UCLA, Los Angeles
17:10-17:30	Discussion	
17:30-18:00	Gates Foundation projects and the Decade of Vaccines	Chris Wilson , Director Global Health Discovery & Translational Sciences program BMGF
18:00-18:20	Discussion	

FRIDAY 10 MAY 2013		Theme Coordinator : Neal Halsey (Baltimore)
SESSION 5- VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS		Chairpersons: Kari Johanssen and Neal Halsey
08:45-09:15	Lessons from previous adverse effects of vaccination and Assessment of causal relationships	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:15-09:35	Discussion	
09:35-10:05	Immunological safety of vaccination (Autoimmune and allergic diseases)	Paul-Henri Lambert , Dir ADVAC
10:05-10:25	Discussion	
10:25-10:40	Break	
10:40-11:10	Population-based post-licensure surveillance	Claudia Vellozzi , CDC
11:10-11:40	Immunization safety in developing country vaccination programs	Philippe Duclos , WHO
11:40-12:20	Common Discussion	
	<u>Lunch</u>	
13:30-14:00	Risk communication: An overview	Noni McDonald , Dalhousie Univ, Halifax Canada
14:00-14:20	Discussion	
SESSION 6- ASSESSING VACCINES IN CLINICAL TRIALS (II)		Chairperson: Hanna Nohynek
14:20-14:50	Introduction to statistical aspects of clinical trials- 2- Statistical assessment of phase 3 trials- 30 min	Peter Smith , LSTMH, UK
14:50-15:10	Discussion	
15:15-18:00	Small group exercise 2: Designing and analyzing the results of selected phase III trials	Objective: To understand how to critically appraise and compare phase III trial results
	Introduction to the group work Exercise:	Hanna Nohynek
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Hanna Nohynek Group 3: - Facilitator: Steve Black Group 4: - Facilitator: Claudia Vellozi Group 5: - Facilitator: Peter Smith Group 6: - Facilitator: Kari Johanssen	

	SATURDAY 11 MAY 2013	
	SESSION 7- ETHICAL ISSUES Ethical considerations related to vaccine trials and implementation of vaccines in organized programs - - principles, guidelines and frameworks	Chairperson: Kari Johansen
08:45-09:30	Ethical considerations in clinical trials of vaccines	Catherine Slack (University of KwaZulu-Natal, South Africa)
09:30-09:55	Ethical considerations in implementation of vaccines in organized programs	Co-lecturing: Betty Dodet (Dodet Bio Science, Lyon) Kari Johansen (European Centre for Disease Prevention and Control , EU)
09:55-10:15	Discussion	
10:15	Pick-up coffee/tea/fruit on the way to group exercise	
10:15-12:45	Small group exercise 3: Ethical issues –topics to be selected with facilitators	Coordinated by Kari Johansen & Betty Dodet (Lyon)
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Catherine Slack Group 3: - Facilitator: Noni McDonald Group 4: - Facilitator: Betty Dodet Group 5: - Facilitator: Kari Johansen Group 6: - Facilitator: Vasee???	

MONDAY 13 MAY 2013		
08:40-09:00	Review and conclusions of the 19 May Ethics session	Cathy Slack
	SESSION 8.1- INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES Approaches to help the decision-making process Case Case # 1 - Pneumococcal and Influenza vaccines in infants and adults	Chairperson: Juhani Eskola , THL, Finland
09:00-09:35	Pneumococcal conjugate vaccines: overview-	Ron Dagan , Soroka Medical Center, Beer Sheva
09:35-10:10	Pneumococcal vaccines: role of viral infections, ecological aspects, and issues related to adult vaccination (including protein vaccines)	Keith Klugman Emory Univ
10:10-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	Understanding vaccine responses in the elderly	Richard Aspinall , Cranfield University, UK
11:30-11:50	Discussion	
11:50-12:20	Understanding responses to polysaccharide and conjugate vaccines in infants and adults	David Goldblatt , Institute of Child Health, London
12:20-12:40	Discussion	
12:40-14:00	<u>Lunch</u>	
14:00-14:40	Influenza biology , new vaccines and vaccination strategies for different age groups	Kathy Neuzil , PATH, Seattle
14:40-15:00	Discussion	
15:00-15:30	Success and challenges with Rotavirus vaccines:	Umesh Parashar CDC
15:30-15:50	Discussion	
15:50-16:10	Break	
16:10-16:50	Special lectures: The population biology of bacterial pathogens and its importance for vaccination strategies	Richard Moxon , Oxford University
17:10-17:40	The challenge of malaria vaccines-	Vasee Moorthy , WHO
17:40-18:00	Discussion	
18:00	Debate with drinks on hot topic e.g. adult vaccination	

TUESDAY 14 MAY 2013		Theme Coordinator : Mark Miller (Bethesda)
	SESSION 8.2 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (2)	Chairperson: Bernard Fritzell , Lyon
	Case-specific study #2: Meningococcal vaccines	
09:00-09:30	Approaches towards new Meningococcal vaccines	Giuseppe Del Giudice, Novartis Vaccines
09:30-09:50	Discussion	
09:50-10:20	The MenA-conjugate experience	Brian Greenwood, UK
10:20-10:40	Discussion	
10:40-11:00	Break	
	Decision-making process for the use of new vaccines at national or regional level	
11:00-11:30	Role of disease burden assessment in the decision-making process	Brad Gessner, Association pour la Médecine Préventive, AMP
11:30-11:50	Discussion	
11:50-12:20	Health economics as a tool in analyzing Vaccine Policy Options	Mark Miller, Fogarty International Center
12:20-12:40	Discussion	
12:40-13:40	Lunch buffet	
13:40-14:10	Challenges and solutions in making evidence-based national vaccination policies and recommendations	Philippe Duclos, WHO
14:10-14:30	Discussion	
14:30-17:30	Small group exercise 4: Decision-making for the evaluation and impact of new vaccines introduced in selected countries: safety and effectiveness	organized by Kari Johanssen, ECDC and Hanna Nohynek
	Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome Group 1 Rota Mark Miller Group 2 Rota XXXX Group 3 HPV Alan Shaw and Hanna Nohynek Group 4 HPV Edwin Asturias and Kari Johanssen Group 5 Influenza Brad Gessner Group 6 PCV Brian Greenwood	
17:40	Soccer game North vs South of the World	

WEDNESDAY 15 MAY 2013		
	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES	Chairpersons: Janet Englund
	1. Vaccination and pregnancy	
09:00-09:30	Main issues and applications in developed and developing countries	Janet Englund , Children's Hospital and Regional Medical Center, Seattle
09:30-09:50	Discussion	
	2. Vaccination in early life	
09:50-10:20	Advantages and limitations	Claire-Anne Siegrist , University of Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
	3. Vaccination schedules	
11:00-11:30	Past, present and future – Is there some rationale?	Edwin Asturias
11:30-11:50	Discussion	
11:50-14:30	Parallel working group sessions (with sandwich lunch)	
	1. Capacity Building in Developing Countries -	Charles Mgone (Executive Director EDCTP)
	2. National decision making for immunization programmes	Allison Mawle , CDC, and Philippe Duclos , WHO
	3. Clinical vaccinology : patients' problem solving	CA Siegrist and Alessandro Diana
	4. new approaches towards vaccination e-registries	Kari Johanssen (ECDC)
14:30-15:00	Info on main ADVAC sponsors activities- Grant opportunities in vaccinology: The EC programmes	Charles Mgone , Executive Director EDCTP
15:00-15:20	Discussion	
15:20-15:40	Break	
	Special lecture	
15:40-16:20	History of Vaccines and Vaccination	Stanley Plotkin , University of Pennsylvania
16:20-16:40	Discussion	
16:40-17:20	THE PLOTKIN LECTURE: Prospects and challenges for Alzheimer's disease vaccines	Cynthia Lemere (Harvard)
17:20-17:40	discussion	
18:00	Departure to Château de Menthon visit and special reception -	

		Theme Coordinator : Edwin Asturias (Guatemala City)
	THURSDAY 16 MAY 2013	
		Chairperson: Edwin Asturias
09:00-09:40	Vaccination in immune-compromised individuals, including HIV positive patients	Claire-Anne Siegrist, University of Geneva
09:40-10:00	discussion	
	<u>Special lectures: New vaccines</u>	
10:00-10:30	CMV vaccines in development	Stanley Plotkin, University of Pennsylvania
10:30-10:50	Discussion	
	Break	
11:10-11:40	HPV vaccines	Margaret Stanley, Cambridge University
11:40-12:00	Discussion	
12:00-12:30	Prospects for dengue and JE vaccines	Hal Margolis , CDC
12:30-12:50	Discussion	
12:50-13:45	<u>Buffet Lunch</u>	
13:45-14:15		
14:15-14:35		
	Elimination or Eradication strategies?	
14:35-15:35	Polio, Measles and rubella	Roland Sutter WHO – 30 min Peter Strebel, WHO- 30 min TBC
15:35-16:15	General discussion coordinated by	
16:15	<u>Presentations by participants and poster discussion</u> Brief presentations by participants and poster discussion	

		Thematic supervisor : Edwin Asturias (Guatemala City)
	FRIDAY 17 MAY 2013	
	SESSION 10: FACING THE MEDIA	Chairperson: Edwin Asturias
09:00-13:00	Interactive session	Deborah Hall , Broadcaster and media affairs consultant, London,
	Introduction to media dynamics: How to best deliver vaccinology r elated messages to different interest groups Lunch	(organized by Edwin Asturias)
14:00-15:00	CME credits Diploma ceremony – Distribution of CD Roms with course slides	Paul Henri Lambert & Claire-Anne Siegrist
15:00	Closure of the Course The educational quality of the course will be certified by Prof. Claire-Anne Siegrist and Dr Hanna Nohynek (CME related issues)	

15th ADVANCED COURSE OF VACCINOLOGY- 2014

MONDAY 12 MAY 2014		Theme Coordinator : Adam Finn (Bristol, UK)
09 :00	Opening	Alain Mérieux, President, Fondation Mérieux
09 :15	Definition of the course objectives	Paul-Henri Lambert, Director of the ADVAC Course
SESSION 1.- THE MULTIFACETED NATURE OF VACCINOLOGY		Chairpersons: Marie-Paule Kieny (WHO) and Claire-Anne Siegrist
09:40-10:25	Opening Lecture: Impact of vaccination on disease epidemiology	Roy Anderson, Director LCNTDR Imperial College, London, UK
10:25-10:45	Discussion	
10:45-11:15	Break	
11:15-11:55	Access to vaccination in GAVI countries and at global level	Stefano Malvoti, Director of Vaccine Implementation, GAVI Alliance
11:55-12:20	Discussion	
12:30-14:00	Lunch	
14:00-14:30	Public and media perception of vaccination	David Salisbury, former Director of Immunisation at the Department of Health , UK
14:30-14:50	Discussion	
14.50-15.20	Role of DC vaccine industry for meeting global needs	Suresh Jadhav, Executive Director, Serum Institute of India,
15:20-15:40	discussion	
15:40-16:00	Break	
16:00-16:30	Development and production of vaccines for global use: the role of vaccine industry	Luis Jodar, Vice president, Global Vaccines, Medicines Development Group and Scientific Affairs at Pfizer Inc
16:30-17:00	discussion	
17:30-19:30	Self-presentation of individual participants (background, interests in life...) & Welcome reception	

TUESDAY 13 MAY 2014		Theme Coordinator : Adam Finn (Bristol, UK)
SESSION 2 - HOW VACCINES WORK		Chairpersons: Adam Finn and Daniel Pinschewer (University of Basel)
09:00-09:30	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses a- B-cell responses	Claire-Anne Siegrist, University of Geneva
09:30-10:00	Discussion	
10:00-10:30	<u>Break</u>	
10:30-11:00	What a vaccinologist should know about the basic aspects of immunological responses b- T-cell responses	Claire-Anne Siegrist, University of Geneva
11:00-11:30	Discussion	
11:30-12:20	Use and limitations of correlates of immunity in vaccinology:	Andrew Pollard, University of Oxford
12:20-12:50	Common discussion	
	<u>Lunch</u>	
14:15-14:45	Immunological basis for responses to mucosal vaccines	Adam Finn, University of Bristol
14:45-15:05	Discussion	
15:05-16:00	Vaccines and Immunological memory Quiz and general discussion	Claire-Anne Siegrist, University of Geneva
16:30-17:10	Special lecture: Vaccine-induced Immunological memory	Rafi Ahmed, Emory University
17:10-17:30	Discussion	
17:45	Debate with drinks on a hot topic	Chair: Adam Finn with Hanna Nohynek

WEDNESDAY 14 MAY 2014		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	SESSION 3 – DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT	Chairpersons: Carole Heilman (NIH)
09:00-09:30	How do vaccines cause adverse events ?	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:30-09:50	Discussion	
09:50-10:20	Vaccine adjuvants	Martin Friede , WHO, Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	Vaccination and narcolepsy	Hanna Nohynek , THL Finland
11:30-11:50	Discussion	
11:50-12:20	From pre-clinical research to vaccine development: Examples of go-no-go decisions	Georges Thiry , IVI
12:20-12:40	Discussion	
	Lunch	
14:00-14:30	Advances in vaccine and immunization technologies	Cristina Casetti , NIAID
14:30-14:50	Discussion	
15:00-17:00	Regulatory considerations e.g. re: hot topic (adjuvants?) Round table debate	Norman Baylor (BCG), Pieter Neels (Vaccine-advice, Belgium) – David Wood (WHO), Eddie Reilly , GSKBio and David Greenberg (Sanofi Pasteur)
17:00-17:30	Lessons from pitfalls experienced in clinical trials and in the registration process	Luc Hessel , Lyon,
17:30-17:50	Discussion	
18:00-19:00	Special debate How to build a Vaccine Biotech development plan towards initial proof of concept? (correlates of protection?, specific target population?, challenge study? etc.)	Carol Heilman (chair) , Michael Wacker (Glycovaxyn), Georges Thiry

		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	THURSDAY 15 MAY 2014	
	SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)	Chairpersons: Hanna Nohynek
09:00-09:40	Clinical trials: an overview of issues to be considered	Myron Levine , University of Maryland, Baltimore, USA
09:40-10:00	Discussion	
10:00-10:30	Introduction to statistical aspects of clinical trials 1- Defining sample size: practical approaches and examples	Peter Smith , LSTMH, UK
10:30-10:50	Discussion	
10:50-11:00	Break	
11:00-13:45	How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise: Group 1: Adam Finn Group 2: Edwin Asturias Group 3: Hanna Nohynek Group 4: George Thiry Group 5: Luc Hessel Group 6: Kari Johanssen	
<i>12:40-13:10 lunch buffet</i>		
13:50-14:20	Special lectures: New vaccines in development (1) HIV vaccines	Brigitte Autran , INSERM, France
14:20-14:40	Discussion	
14:40-15:15	Special lectures: New vaccines in development (2) Challenges and prospects for new tuberculosis vaccines	David Lewis , Uni Surrey UK
15:15-15:35	Discussion	
15:35-15:55	Break	
15:55-16:25	Clinical trials: role of a DSMB- (with several examples of intervention)	Penny Heaton , BMGF
16:25-16:40	Discussion	
16:40-17:10	Assessing herd protection and vaccine effectiveness	John Clemens , International Centre for Diarrheal Disease Research (icddr,b), Bangladesh
17:10-17:30	Discussion	
17:30-18:00	Special lectures: Global challenges for pertussis vaccines	Scott Halperin , Dalhousie Univ, Halifax. Canada
18:00-18:20	Discussion	

FRIDAY 16 MAY 2014		Theme Coordinator : Neal Halsey (Baltimore)
	SESSION 5- VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS	Chairpersons: Kari Johanssen and Neal Halsey
08:45-09:15	Lessons from previous adverse effects of vaccination and Assessment of causal relationships	Neal Halsey, Johns Hopkins B. School of Public Health, Baltimore
09:15-09:35	Discussion	
09:35-10:05	Immunological safety of vaccination (Autoimmune and allergic diseases)	Paul-Henri Lambert, Dir ADVAC
10:05-10:25	Discussion	
10:25-10:40	Break	
10:40-11:10	Population-based post-licensure surveillance	Nick Andrews, HPA, UK
11:10-11:40	Immunization safety in developing country vaccination programs	Philippe Duclos , WHO
11:40-12:20	Common Discussion	
	<u>Lunch</u>	
13:30-14:00	Risk communication: An overview	Noni McDonald, Dalhousie Univ, Halifax Canada
14:00-14:20	Discussion	
	SESSION 6- ASSESSING VACCINES IN CLINICAL TRIALS (II)	Chairperson: Hanna Nohynek
14:20-14:50	Introduction to statistical aspects of clinical trials- 2- Statistical assessment of phase 3 trials- 30 min	Peter Smith , LSTMH, UK
14:50-15:10	Discussion	
15:15-18:00	Small group exercise 2: Designing and analyzing the results of selected phase III trials	Objective: To understand how to critically appraise and compare phase III trial results
	Introduction to the group work Exercise:	Hanna Nohynek
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Hanna Nohynek Group 3: - Facilitator: Group 4: - Facilitator: Group 5: - Facilitator: Peter Smith Group 6: - Facilitator: Kari Johanssen	
18:00	Workshops (voluntary basis) on (i) logistics of vaccine supply – Ph.. Duclos, & Diana Chang Blanc (WHO) (ii) causality assessment –N. Halsey	

SATURDAY 17 MAY 2014		Theme Coordinator : Kari Johansen (ECDC)
	SESSION 7- ETHICAL ISSUES Ethical considerations related to vaccine trials and implementation of vaccines in organized programs - - principles, guidelines and frameworks	Chairperson: Kari Johansen
08:45-09:20	Ethical considerations in clinical trials of vaccines	Catherine Slack (University of KwaZulu-Natal, South Africa)
09:20-09:30	Questions	
09:30-10:30	Panel discussion – a sample of ethical considerations <ul style="list-style-type: none"> - Placebo versus comparator vaccine in clinical trials (Pieter Neels) - Ethics and regulation for comparative effectiveness research (Hanna Nohynek) - Religious objections to vaccines (Neal Halsey) 	Scientific panel Neal Halsey Noni McDonald Pieter Neels Hanna Nohynek Betty Dodet Kari Johansen
10:30	Pick-up and bring coffee/tea/fruit to group exercise	
10:30-13:00	Small group exercise 3: Ethical issues – topics to be selected with facilitators	Coordinated by Kari Johansen, Betty Dodet and Catherine Slack
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Catherine Slack Group 3: - Facilitator: Noni McDonald Group 4: - Facilitator: Betty Dodet - Rana Group 5: - Facilitator: Kari Johansen Group 6: - Facilitator: Pieter Neels - Vasee	

		Theme Coordinator : Mark Miller (Bethesda)
	MONDAY 19 MAY 2014	
08:40-09:00	Review and conclusions of the 19 May Ethics exercise	Cathy Slack
	SESSION 8.1- INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (1)	Chairperson: Juhani Eskola , THL, Finland
09:00-09:30	Role of disease burden assessment in the decision-making process	Brad Gessner , Association pour la Médecine Préventive, AMP
09:30-09:45	Discussion	
9:45-10:15	Health economics as a tool in analyzing Vaccine Policy Options	Mark Miller , Fogarty International Center
10:15-10:30	Discussion	
	Break	
10:50-11:20	Challenges and solutions in making evidence-based national vaccination policies and recommendations	Philippe Duclos , WHO
11:20-11:50	Discussion and common debate on efficiency vs equity	Brad Gessner, Mark Miller, Philippe Duclos
11:50-12:30	Understanding responses to polysaccharide and conjugate vaccines in infants and adults	David Goldblatt , Institute of Child Health, London
12:30-12:50	Discussion	
12:50-14:00	<u>Lunch</u>	
14:00-14:35	Pneumococcal conjugate vaccines: overview-	Ron Dagan , Soroka Medical Center, Beer Sheva
14:35-15:10	Pneumococcal vaccines: role of viral infections, ecological aspects, and issues related to adult vaccination (including protein vaccines)	Keith Klugman BMGF
15:10-15:45	Common discussion	
15:45-16:10	Break	
16:10-16:40	The MenA-conjugate experience	Brian Greenwood , UK
16:40-17:20	Present approaches towards group B and multivalent Meningococcal vaccines	Giuseppe Del Giudice , Novartis Vaccines
17:20-17:30	Common Discussion	
18:00	Debate on MenB vaccine introduction: is it a priority?	David Goldblatt , Mark Miller , Rino Rappuoli (Novartis), Juhani Eskola (moderator)

TUESDAY 20 MAY 2014		Theme Coordinator : Mark Miller (Bethesda)
	SESSION 8.2 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (2)	Chairperson: Bernard Fritzell , Bordeaux
08:45-09:15	Understanding vaccine responses in the elderly	Richard Aspinall, Cranfield University, UK
09:15-09:35	Discussion	
09:35-10:05	Influenza biology , new vaccines and vaccination strategies for different age groups	Kathy Neuzil, PATH, Seattle
10:05-10:25	Discussion	
10:25-10:45	Break	
10:45-11:15	Success and challenges with Rotavirus vaccines:	Umesh Parashar CDC
11:15-11:35	Discussion	
11:35-12:15	Special lecture: The population biology of bacterial pathogens and its importance for vaccination strategies	Richard Moxon, Oxford University
12:15-12:35	Discussion	
12:35-13:45	lunch	
13:45-14:15	The challenge of malaria vaccines and of their potential introduction-	Vasee Moorthy , WHO
14:15-14:35	discussion	
14:40-17:20	Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness	organized by Kari Johanssen, ECDC and Hanna Nohynek
	Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome Group 1 Rota Mark Miller Group 2 Rota XXXX Group 3 HPV Alan Shaw and Hanna Nohynek Group 4 HPV Edwin Asturias and Kari Johanssen Group 5 Influenza Brad Gessner Group 6 PCV Brian Greenwood	
17:45	Soccer game North vs South of the World	

		Theme Coordinator : Edwin Asturias
	WEDNESDAY 21 MAY 2014	
	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES	Chairpersons: Alan Shaw (Vedantra)
	1. Vaccination and pregnancy	
09:00-09:30	Main issues and applications in developed and developing countries	Janet Englund , Children's Hospital and Regional Medical Center, Seattle
09:30-09:50	Discussion	
	2. Vaccination in early life	
09:50-10:20	Advantages and limitations	Claire-Anne Siegrist , University of Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
	3. Vaccination schedules	
11:00-11:30	Past, present and future – Is there some rationale?	Edwin Asturias (Children's Hospital Colorado)
11:30-11:50	Discussion	
11:50-15:20	Parallel working group sessions (with sandwich lunch)	
	1. Opportunities and challenges for assessing new vaccines in Developing Countries -	Chris Wilson (BMGF) , Pauline Beattie (EDCTP))
	2.National decision making for immunization programmes	Jane Seward , CDC, Philippe Duclos ,WHO and Carine Dochez (NESI)
	3.Clinical vaccinology : patients' problem solving	Claire-Anne Siegrist and Alessandro Diana (UNIGE)
	4. new approaches towards vaccination e-registries	Kari Johanssen (ECDC)
15:20-15:40	Break	
	Special lecture	
15:40-16:20	History of Vaccines and Vaccination	Stanley Plotkin , University of Pennsylvania
16:20-16:40	Discussion	
16:40-17:20	THE PLOTKIN LECTURE: What can we expect from Systems Biology in the field of vaccines?	Alan Aderem President; Seattle Biomedical Research Institute
17:20-17:40	discussion	
18:00	Departure to Château de Menthon visit and special reception -	

		Theme Coordinator : Edwin Asturias
	THURSDAY 22 MAY 2014	
		Chairperson: Edwin Asturias
09:00-09:40	Vaccination in immune-compromised individuals, including HIV positive patients	Claire-Anne Siegrist, University of Geneva
09:40-10:00	discussion	
	<u>Special lectures: New vaccines</u>	
10:00-10:30	CMV vaccines in development	Stanley Plotkin, University of Pennsylvania
10:30-10:50	Discussion	
	Break	
11:10-11:40	HPV vaccines	Margaret Stanley, Cambridge University
11:40-12:00	Discussion	
12:00-12:30	Prospects for dengue and JE vaccines	Hal Margolis , CDC
12:30-12:50	Discussion	
12:50-13:45	<u>Buffet Lunch</u>	
13:45-14:15		
14:15-14:35		
	Elimination or Eradication strategies?	
14:35-15:35	Polio, focusing on new strategies Measles and rubella,	Roland Sutter WHO – 30 min Peter Strebel, WHO- 30 min TBC
15:35-16:15	General discussion	Stanley Plotkin
16:15-16:45	Introduction of rabies vaccines into immunization programs	Deborah Briggs Executive Director, Global Alliance for Rabies Control
16:45-17:05	Discussion	
17:05	Introducing the ADVAC alumni network	Josette Najjar (FMER)
17:30	<u>Presentations by participants and poster discussion</u> Brief presentations by participants and poster discussion	

	FRIDAY 23 MAY 2014	
	SESSION 10: FACING THE MEDIA	Chairperson: Edwin Asturias
09:00-13:00	Interactive session	Deborah Hall , Broadcaster and media affairs consultant, London,
	Introduction to media dynamics: How to best deliver vaccinology r elated messages to different interest groups Lunch	(organized by Edwin Asturias)
14:00-15:00	CME credits Diploma ceremony – Distribution of CD Roms with course slides	Paul Henri Lambert & Claire-Anne Siegrist
15:00	Closure of the Course The educational quality of the course will be certified by Prof. Claire-Anne Siegrist and Dr Hanna Nohynek (CME related issues)	

16th ADVANCED COURSE OF VACCINOLOGY- 2015

MONDAY 11 MAY 2015		Theme Coordinator : Adam Finn (Bristol, UK)
09 :00	Opening	Alain Mérieux, President, Fondation Mérieux
09 :15	Definition of the course objectives	Paul-Henri Lambert, Director of the ADVAC Course
SESSION 1.- THE MULTIFACETED NATURE OF VACCINOLOGY		Chairpersons: Marie-Paule Kieny (WHO) and Claire-Anne Siegrist
09:40-10:25	Opening Lecture: Impact of vaccination on disease epidemiology	Roy Anderson, Director LCNTDR Imperial College, London, UK
10:25-10:45	Discussion	
10:45-11:15	Break	
11:15-11:55	Access to vaccination in GAVI countries and at global level	Stefano Malvoti, GAVI Alliance
11:55-12:20	Discussion	
12:30-14:00	Lunch	
14:00-14:30	How to develop a new program of immunization	David Salisbury, former Director of Immunisation at the Department of Health , UK
14:30-14:50	Discussion	
14.50-15.20	Role of DC vaccine industry for meeting global needs	Suresh Jadhav, Executive Director, Serum Institute of India,
15:20-15:40	Discussion	
15:40-16:00	Break	
16:00-16:30	Development and production of vaccines for global use: the role of vaccine industry	Luis Jodar, Vice president, Global Vaccines, Medicines Development Group and Scientific Affairs at Pfizer Inc
16:30-17:00	Discussion	
17:30-19:30	Self-presentation of individual participants (background, interests in life...) & Welcome reception	

TUESDAY 12 MAY 2015		Theme Coordinator : Adam Finn (Bristol, UK)
SESSION 2 - HOW VACCINES WORK		Chairpersons: Adam Finn and Daniel Pinschewer (University of Basel)
09:00-09:30	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses a- B-cell responses	Claire-Anne Siegrist, University of Geneva
09:30-10:00	Discussion	
10:00-10:30	<u>Break</u>	
10:30-11:00	What a vaccinologist should know about the basic aspects of immunological responses b- T-cell responses	Claire-Anne Siegrist, University of Geneva
11:00-11:30	Discussion	
11:30-12:20	Use and limitations of correlates of immunity in vaccinology:	Andrew Pollard, University of Oxford
12:20-12:50	Common discussion	
	<u>Lunch</u>	
14:15-14:45	Vaccines and Mucosal immunity	Adam Finn, University of Bristol
14:45-15:05	Discussion	
15:05-16:00	Vaccines and Immunological memory Quiz and general discussion	Claire-Anne Siegrist, University of Geneva
16:30-17:00	Vaccine-induced T cell responses – CD8 T cells	Daniel Pinschewer, University of Basel
17:00-17:20	Discussion	
17 45	Debate with drinks on a hot topic Mandatory vaccination (?)	Chair: Adam Finn with Hanna Nohynek

WEDNESDAY 13 MAY 2015		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	SESSION 3 – DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT	Chairpersons: Carole Heilman (NIH)
09:00-09:40	Clinical trials: an overview of issues to be considered	Myron Levine , University of Maryland, Baltimore, USA
09:40-10:00	Discussion	
10:00-10:30	How do vaccines cause adverse events?	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
10:30-10:50	Discussion	
10:50-11:10	Break	
11:10-11:40	Vaccine adjuvants	Martin Friede , WHO, Geneva
11:40-12:00	Discussion	
12:00-12:30	Vaccination and narcolepsy	Hanna Nohynek , THL Finland
12:30-12:50	Discussion	
	Lunch	
14:00-14:30	From pre-clinical research to vaccine development: Examples of go-no-go decisions	Georges Thiry , France
14:30-14:50	Discussion	
15:00-17:00	Regulatory considerations e.g. re: hot topic (Fast track pathways: the Ebola example?) Round table debate	Chair: Carole Heilman Norman Baylor (BCG), Pieter Neels (Vaccine-advice, Belgium), David Wood (WHO), Pascal Peeters , GSKBio and David Greenberg (Sanofi Pasteur)
17:00-17:30	Special lectures: New vaccines in development (1) HIV vaccines	Brigitte Autran , INSERM, France
17:30-17:50	Discussion	
18:00-19:00	Special debate How to build a Vaccine Biotech development plan towards initial proof of concept and have it funded by investors? (correlates of protection?, specific target population?, challenge study? etc.)	Carol Heilman (chair), Michael Wacker (Glycovaxyn), Georges Thiry and SME participants

		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
THURSDAY 14 MAY 2015		
		Chairpersons: Hanna Nohynek
09:00-09:30	Advances in vaccine and immunization technologies	Cristina Cassetti , NIAID
09:30-09 :50	Discussion	
	SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)	
09:50-10:20	Introduction to statistical aspects of clinical trials 1- Defining sample size: practical approaches and examples	Peter Smith , LSTMH, UK
10:20:10:40	Discussion	
10:40-11:00	Break	
11:00-13:45	How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise: Group 1: Adam Finn Group 2: Edwin Asturias Group 3: Hanna Nohynek Group 4: George Thiry Group 5: Luc Hessel Group 6: Kari Johansen	
<i>12:40-13:10 lunch buffet</i>		
13.50-14.20	Lessons from pitfalls experienced in clinical trials and in the registration process	Luc Hessel, Lyon
14:20-14:40	Discussion	
14:40-15:15	Special lectures: New vaccines in development (2) Challenges and prospects for new tuberculosis vaccines	David Lewis, Imperial College, London, UK
15:15-15:35	Discussion	
15:35-15:55	Break	
15:55-16:25	Clinical trials: role of a DSMB (with several examples of intervention)	Penny Heaton , BMGF
16:25-16:40	Discussion	
16:40-17:10	The challenge of malaria vaccines and of their potential introduction	Vasee Moorthy , WHO
17:10-17:30	Discussion	
17:30-18:00	Special lectures: Global challenges for pertussis vaccines	Scott Halperin, Dalhousie University, Halifax, Canada
18:00-18:20	Discussion	

FRIDAY 15 MAY 2015		Theme Coordinator : Neal Halsey (Baltimore)
SESSION 5- VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS		Chairpersons: Kari Johansen and Neal Halsey
08:45-09:15	Lessons from previous adverse effects of vaccination and Assessment of causal relationships	Neal Halsey, Johns Hopkins B. School of Public Health, Baltimore
09:15-09:35	Discussion	
09:35-10:05	Immunological safety of vaccination (Autoimmunity)	Paul-Henri Lambert, Dir ADVAC
10:05-10:25	Discussion	
10:25-10:40	Break	
10:40-11:10	Population-based post-licensure surveillance	Nick Andrews, HPA, UK
11:10-11:40	Immunization safety in developing country vaccination programs	Philippe Duclos , WHO
11:40-12:20	Common Discussion	
	<u>Lunch</u>	
13:30-14:00	Vaccine hesitancy and Risk communication: An overview	Noni McDonald, Dalhousie Univ, Halifax Canada
14:00-14:20	Discussion	
SESSION 6- ASSESSING VACCINES IN CLINICAL TRIALS (II)		Chairperson: Hanna Nohynek
14:20-14:50	Introduction to statistical aspects of clinical trials 2- Statistical assessment of phase 3 trials - 30 mins.	Peter Smith , LSTMH, UK
14:50-15:10	Discussion	
15:10-17:45	Small group exercise 2: Designing and analyzing the results of selected phase III trials	Objective: To understand how to critically appraise and compare phase III trial results
	Introduction to the group work Exercise:	Hanna Nohynek
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Hanna Nohynek Group 3: - Facilitator: Group 4: - Facilitator: Group 5: - Facilitator: Peter Smith Group 6: - Facilitator: Kari Johansen	
17:45-17:55	Examples of vaccine- related projects in IMI	Angela Wittelsberger, Innovative Medicines Initiative (IMI)
17:55-18:00	Discussion	
18:00	Debate on challenge trials, with IABS participation	Cristina Casseti , Peter Neels, Joris Vandeputte (chair),

SATURDAY 16 MAY 2015		Theme Coordinator : Kari Johansen (ECDC)
	SESSION 7- ETHICAL ISSUES Ethical considerations related to vaccine trials and implementation of vaccines in organized programs - principles, guidelines and frameworks	Chairperson: Kari Johansen
08:45-09:20	Ethical considerations in clinical trials of vaccines	Catherine Slack (University of KwaZulu-Natal, South Africa)
09:20-09:30	Questions	
09:30-10:30	Panel discussion – a sample of ethical considerations <ul style="list-style-type: none"> - Religious and philosophical objections to vaccines (Neal Halsey) Comments by Ethical expert - Ethics and regulation for comparative effectiveness research (Hanna Nohynek) Comments by Ethical Expert - Ethical dilemmas for conduct of vaccine trials in pregnant women – referral of a recent discussion held at SAGE on hepatitis E vaccines (Noni McDonald & Kari Johansen) Comments by Ethical expert 	Scientific panel Moderator: Kari Johansen Ethical expert: Catherine Slack Neal Halsey Noni McDonald Pieter Neels Hanna Nohynek Betty Dodet Kari Johansen Rana Hajjeh Jane Seward
10:30	Pick-up and bring coffee/tea/fruit to group exercise	
10:30-13:00	Small group exercise 3: Ethical issues – topics to be selected with facilitators	Coordinated by Kari Johansen, Betty Dodet and Catherine Slack
	Group 1:- Facilitator: Edwin Asturias Group 2:- Facilitator: Catherine Slack Group 3:- Facilitator: Noni McDonald Group 4:- Facilitator: Betty Dodet - Rana Hajjeh Group 5:- Facilitator: Kari Johansen Group 6:- Facilitator: Pieter Neels - Vasee Moorthy	

		Theme Coordinator : Mark Miller (Bethesda)
	MONDAY 18 MAY 2015	
08:40-09:00	Review and conclusions of the 16 May Ethics session	Cathy Slack
	SESSION 8.1- INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (1)	Chairperson: Juhani Eskola , THL, Finland
09:00-09:30	Assessing herd protection and vaccine effectiveness	John Clemens , ICCDR-B, Bangladesh
09:30-09:50	Discussion	
09:50-10:20	Role of disease burden assessment in the decision-making process	Brad Gessner , Association pour la Médecine Préventive, AMP
10:20-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	Health economics as a tool in analyzing Vaccine Policy Options	Mark Miller , Fogarty International Center
11:30-11:50	Discussion	
11:50-12:20	Challenges and solutions in making evidence-based national vaccination policies and recommendations	Philippe Duclos , WHO
12:20-12:40	Discussion	
12:40-13:45	Lunch	
13:45-14:25	Understanding responses to polysaccharide and conjugate vaccines in infants and adults	David Goldblatt , Institute of Child Health, London
14:25-14:45	Discussion	
14:45-15:30	Pneumococcal conjugate vaccines: overview- (infant and adults) 45 min	Ron Dagan , Soroka Medical Center, Beer Sheva
15:30-15:50	Discussion	
15:50-16:10	Break	
16:10-16:50	Meningococcal vaccines (including the MenA-conjugate experience) 40 min	Brian Greenwood , UK
16:50-17:10	Discussion	
17:10-17:50	Special lecture: The population biology of bacterial pathogens and its importance for vaccination strategies	Richard Moxon , Oxford University
17:50-18:10	Discussion	
18:15	Debate on Men B vaccine introduction	Juhani Eskola (moderator) , Richard Moxon , Mark Miller ,

TUESDAY 19 MAY 2015		Theme Coordinator : Mark Miller (Bethesda)
	SESSION 8.2 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (2)	Chairperson: Bernard Fritzell , Bordeaux
09:00-09:30	Understanding vaccine responses in the elderly	Richard Aspinall, Anglia Ruskin University, UK
09:30-09:50	Discussion	
09:50-10:30	Influenza biology, new vaccines and vaccination strategies for different age groups	Kathy Neuzil, PATH, Seattle
10:30-10:50	Discussion	
10:50-11:10	Break	
11:10-11:40	Success and challenges with Rotavirus vaccines:	Umesh Parashar CDC
11:40-12:00	Discussion	
12:00-13:15	Lunch	
13:15-16:00	Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness	organized by Kari Johansen, ECDC and Hanna Nohynek
	Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome Group 1 Rota Mark Miller Group 2 Rota XXXX Group 3 HPV Alan Shaw and Hanna Nohynek Group 4 HPV Edwin Asturias and Kari Johansen Group 5 Influenza Brad Gessner Group 6 Malaria Brian Greenwood	
16:00-16:40	History of Vaccines and Vaccination	Stanley Plotkin, University of Pennsylvania
16:40-17:00	Discussion	
17:30	Soccer game North vs South of the World	
19:00	Introducing the ADVAC alumni network	Josette Najjar (FMER)

		Theme Coordinator : Edwin Asturias
	WEDNESDAY 20 MAY 2015	
	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES	Chairpersons: Alan Shaw , Boston
	1. Vaccination and pregnancy	
09:00-09:30	Scientific basis, main issues and applications	Janet Englund , Children's Hospital and Regional Medical Center, Seattle
09:30-09:50	Discussion	
09:50-10:20	Introduction of Vaccines for Maternal-neonatal health (challenges and candidates: rubella, TT, TdaP, influenza, RSV, GBS)	Janet Englund
10:20-10:40	Discussion	
10:40-11:00	Break	
	2. Vaccination in early life	
11:00-11:30	Advantages and limitations	Claire-Anne Siegrist , University of Geneva
11:30-11:50	Discussion	
	3. Vaccination schedules	
11:50-12:20	Past, present and future – is there some rationale?	Edwin Asturias (Children's Hospital Colorado)
12:20-12:40	Discussion	
12:40-16:00	Parallel working group sessions (with sandwich lunch)	
	1.Opportunities and challenges for assessing new vaccines in Developing Countries	Chris Wilson (BMGF) and Pauline Beattie (EDCTP)
	2.National decision-making for immunization programmes	Jane Seward , CDC, and Philippe Duclos , WHO and Carine Dochez (NESI)
	3.Clinical vaccinology: patients' problem solving	Claire-Anne Siegrist and Alessandro Diana (UNIGE)
	4. New approaches towards vaccination e-registries	Kari Johansen (ECDC)
16:00-16:20	Break	
	Special lecture	
16:20-17:10	THE PLOTKIN LECTURE: Lessons from the Ebola Outbreak	Marie-Paule Kieny , Assistant Director-General, WHO
17:10-17:40	Discussion	
18:00	Departure to Château de Menthon visit and special reception	

		Theme Coordinator : Edwin Asturias
	THURSDAY 21 MAY 2015	
		Chairperson: Edwin Asturias
09:00-09:40	Vaccination in immune-compromised individuals, including HIV positive patients	Claire-Anne Siegrist, University of Geneva
09:40-10:00	Discussion	
	<u>Special lectures: New vaccines</u>	
10:00-10:30	CMV vaccines in development	Stanley Plotkin, University of Pennsylvania
10:30-10:50	Discussion	
10:50-11:10	Break	
11:10-11:40	HPV vaccines	Margaret Stanley, Cambridge University
11:40-12:00	Discussion	
12:00-12:30	Prospects for dengue and JE vaccines	Hal Margolis , CDC
12:30-12:50	Discussion	
12:50-13:45	<u>Buffet Lunch</u>	
13:45-14:15	Progress with RSV vaccines	Barney Graham (NIH)
14:15-14:35	Discussion	
	Elimination or Eradication strategies?	
14:35-15:35	Polio, focusing on new strategies Measles and rubella	Ananda Bandyopadhyay, Bill & Melinda Gates Foundation - 30 mins- Peter Strebel, WHO - 30 min
15:35-16:15	General discussion	Stanley Plotkin
16:30	CME credits Diploma ceremony The educational quality of the course will be certified by Prof. Claire-Anne Siegrist and Dr Hanna Nohynek (CME related issues)	Stanley Plotkin, Paul Henri Lambert and Christophe Longuet

	FRIDAY 22 MAY 2015	
	SESSION 10: FACING THE MEDIA	Chairperson: Edwin Asturias
09:00-13:00	Interactive session	Deborah Hall , Broadcaster and media affairs consultant, London,
	Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups Lunch	(organized by Edwin Asturias)
14:300	Closure of the Course	

17th ADVANCED COURSE OF VACCINOLOGY- 2016

MONDAY 23 MAY 2016		Theme Coordinator : Adam Finn (Bristol, UK)
08 :15	<i>Briefing session on the iPad based system of information during ADVAC</i>	
09 :00	Opening	Alain Mérieux , President, Fondation Mérieux
09 :15	Definition of the course objectives	Paul-Henri Lambert , Director of the ADVAC Course
SESSION 1.- THE MULTIFACETED NATURE OF VACCINOLOGY		Chairpersons: Claire-Anne Siegrist and Paul-Henri Lambert
09:40-10:25	Opening Lecture: Impact of vaccination on disease epidemiology	Roy Anderson , Director LCNTDR Imperial College, London, UK
10:25-10:45	Discussion	
10:45-11:15	Break	
11:15-11:45	Development and production of vaccines for global use: the role of vaccine industry	Luis Jodar , Vice president, Global Vaccines, Medicines Development Group and Scientific Affairs at Pfizer Inc
11:45-12:10	Discussion	
12:20-13:50	<u>Lunch</u>	
13:50-14:30	Access to vaccination in GAVI countries and at global level	Jon Pearman , GAVI Alliance
14:30-14:50	Discussion	
14.50-15.20	How to develop a new program of immunization	David Salisbury , former Director of Immunisation at the Department of Health , UK
15:20-15:40	Discussion	
15:40-16:00	Break	
16:00-16:30	Role of DC vaccine industry for meeting global needs	Suresh Jadhav , Executive Director, Serum Institute of India,
16:30-17:00	Discussion	
17:30-19:30	Self-presentation of individual participants (background, interests in life...) & Welcome reception	

TUESDAY 24 MAY 2016		Theme Coordinator : Adam Finn (Bristol, UK)
SESSION 2 - HOW VACCINES WORK		Chairpersons: Adam Finn and Daniel Pinschewer (University of Basel)
09:00-09:30	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses a- B-cell responses	Claire-Anne Siegrist , University of Geneva
09:30-10:00	Discussion	
10:00-10:30	<u>Break</u>	
10:30-11:00	What a vaccinologist should know about the basic aspects of immunological responses b- T-cell responses	Claire-Anne Siegrist , University of Geneva
11:00-11:30	Discussion	
11:30-12:20	Use and limitations of correlates of immunity in vaccinology:	Andrew Pollard , University of Oxford
12:20-12:50	Common discussion	
	<u>Lunch</u>	
14:15-14:45	Vaccines and Mucosal immunity	Adam Finn , University of Bristol
14:45-15:05	Discussion	
15:05-16:00	Vaccines and Immunological memory Quiz and general discussion	Claire-Anne Siegrist , University of Geneva
16:00-16:20	Break	
17:00	Debate with drinks on a hot topic Mandatory vaccination	Chair: Adam Finn with Hanna Nohynek

WEDNESDAY 25 MAY 2016		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	SESSION 3 – DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT	Chairpersons: Carole Heilman (NIH)
09:00-09:40	Clinical trials: an overview of issues to be considered	Myron Levine , University of Maryland, Baltimore, USA
09:40-10:00	Discussion	
10:00-10:30	How do vaccines cause adverse events?	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
10:30-10:50	Discussion	
10:50-11:10	Break	
11:10-11:40	Vaccine adjuvants	Martin Friede , WHO, Geneva
11:40-12:00	Discussion	
12:00-12:30	From pre-clinical research to vaccine development: Examples of go-no-go decisions	Georges Thiry , France
12:30-12:50	Discussion	
	Lunch	
14:00-14:30	Assessing herd protection and vaccine effectiveness	John Clemens , ICCDR-B, Bangladesh
14:30-14:50	Discussion	
15:00-16:45	Regulatory considerations e.g. re: hot topic (Emergency acceleration of vaccine development: the Ebola example) Round table debate	Chair: Carole Heilman Norman Baylor (BCG), Pieter Neels (Vaccine-advice, Belgium), Ozzie Berger , GSKBio and David Greenberg (Sanofi Pasteur)
16:45-17:00	Break	
17:00-17:40	THE 1ST LAMBERT LECTURE From autoimmunity to immunity... and back? Relevance to vaccines.	Paul-Henri Lambert , Dir ADVAC
17:40-18:00	Discussion	
18:00-19:00	Social get together	

THURSDAY 26 MAY 2016		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
		Chairpersons: Hanna Nohynek
09:00-09:30	Advances in vaccine and immunization technologies	Cristina Casetti , NIAID
09:30-09 :50	Discussion	
	SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)	
09:50-10:20	Introduction to statistical aspects of clinical trials 1- Defining sample size: practical approaches and examples	Peter Smith , LSTMH, UK
10:20:10:40	Discussion	
10:40-11:00	Break	
11:00-13:45	How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise: Group 1: Adam Finn Group 2: Edwin Asturias Group 3: Hanna Nohynek Group 4: George Thiry Group 5: Luc Hessel Group 6: Kari Johansen	
<i>12:40-13:10 lunch buffet</i>		
13.50-14.20	Special lectures: New vaccines in development (1) Challenges and prospects for new tuberculosis vaccines	David Lewis , Imperial Centre for Translational and Experimental Medicine, London
14:20-14:40	Discussion	
14:40-15:10	Clinical trials: role of a DSMB (with several examples of intervention)	Penny Heaton , BMGF
15:10-15:30	Discussion	
15:30-15:550	Break	
15:50-16:20	Special lectures: Global challenges for pertussis vaccines	Scott Halperin , Dalhousie University, Halifax, Canada
16:20-16:40	Discussion	
16:40-17:30	Debate on challenge trials, with IABS participation	Peter Neels , Kari Johansen , Joris Vandeputte (chair) ,
17:30-19:00	Special debate How to build a Vaccine Biotech development plan towards initial proof of concept and have it funded by investors? (correlates of protection?, specific target population?, challenge study? etc.)	Carol Heilman (chair) , Michael Wacker (Glycovaxyn) , Georges Thiry and SME participants

	FRIDAY 27 MAY 2016	Theme Coordinator : Neal Halsey (Baltimore)
	SESSION 5– VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS	Chairpersons: Kari Johansen and Neal Halsey
09:00-09:30	Lessons from previous adverse effects of vaccination and Assessment of causal relationships	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:30-09:50	Discussion	
09:50-10:20	Population-based post-licensure surveillance	Nick Andrews , HPA, UK
10:20-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	Immunization safety in developing country vaccination programs	Philippe Duclos , WHO
11:30-11:50	Discussion	
11:50-12:20	Vaccine hesitancy and Risk communication: An overview	Noni McDonald , Dalhousie Univ, Halifax Canada
12:20-12:40	Discussion	
12:40-14:00	<u>Lunch</u>	
	SESSION 6– ASSESSING VACCINES IN CLINICAL TRIALS (II)	Chairperson: Hanna Nohynek
14:00-14:30	Introduction to statistical aspects of clinical trials 2- Statistical assessment of phase 3 trials - 30 mins.	Peter Smith , LSTMH, UK
14:30-14:50	Discussion	
15:00-17:30	Small group exercise 2: Designing and analyzing the results of selected phase III trials	Objective: To understand how to critically appraise and compare phase III trial results
	Introduction to the group work Exercise:	Hanna Nohynek
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Hanna Nohynek Group 3: - Facilitator: Penny Heaton Group 4: - Facilitator: Brad Gessner Group 5: - Facilitator: Peter Smith Group 6: - Facilitator: Kari Johansen	
17:30-18:00	Zika : emerging issues	Cristina Cassetti , NIAID
18:00-18:20	Discussion	

SATURDAY 28 MAY 2016		Theme Coordinator : Kari Johansen (ECDC)
	SESSION 7- ETHICAL ISSUES Ethical considerations related to vaccine trials and implementation of vaccines in organized programs - principles, guidelines and frameworks	Chairperson: Kari Johansen
08:45-09:20	Ethical considerations in clinical trials of vaccines	Catherine Slack (University of KwaZulu-Natal, South Africa)
09:20-09:30	Questions	
09:30-10:30	Interactive discussion on a sample of ethical considerations related to conduct of vaccine programmes <ul style="list-style-type: none"> - An introduction to actual and perceived religious and philosophical objections to vaccination (Neal Halsey) Final comments following discussion by Ethical expert (Catherine Slack) - An introduction to ethical dilemmas and other considerations for vaccination in acute humanitarian emergencies (Melanie Marti, Rana Hajjeh, MSF) Final comments following discussion by Ethical expert (Catherine Slack) 	Scientific panel Moderator: Kari Johansen Ethical expert: Catherine Slack Neal Halsey Noni McDonald Pieter Neels Hanna Nohynek Betty Dodet Kari Johansen Rana Hajjeh
10:30	Pick-up and bring coffee/tea/fruit to group exercise	
10:30-13:00	Small group exercise 3: ETHICAL CONSIDERATIONS IN MALARIA VACCINE TRIALS	Coordinated by Kari Johansen, Betty Dodet and Catherine Slack
	Group 1:- Facilitator: Rana Hajjeh Group 2: - Facilitator: Catherine Slack Group 3: - Facilitator: Noni McDonald Group 4: - Facilitator: Betty Dodet Group 5: - Facilitator: Kari Johansen Group 6: - Facilitator: Pieter Neels	

MONDAY 30 MAY 2016		Theme Coordinator : Mark Miller (Bethesda)
		Chairperson: Juhani Eskola , THL, Finland
08:40-09:00	Review and conclusions of the 28 May Ethics session	Cathy Slack
09:00-09:30	Special Lectures Vaccine-induced immunological memory	Rafi Ahmed, Emory University
09:30-09:50	Discussion	
09:50-10:20	Vaccination and narcolepsy	Hanna Nohynek, THL Finland
10:20-10:50	Discussion	
10:50-11:10	Break	
	SESSION 8.1- INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (1)	Chairperson: Juhani Eskola , THL, Finland
11:10-11:40	Role of disease burden assessment in the decision-making process	Brad Gessner, Agence de Médecine Préventive, AMP
11:40-12:00	Discussion	
12:00-12:30	Health economics as a tool in analyzing Vaccine Policy Options	Mark Miller, Fogarty International Center
12:30-12:50	Discussion	
12:50-14:00	Lunch	
14:00-14:30	Challenges and solutions in making evidence-based national vaccination policies and recommendations	Philippe Duclos, WHO
14:30-14:50	Discussion	
14:50-15:20	Immunization coverage gaps: overcoming the chronic challenges	Jean-Marie Okwo Bele (WHO)
15:20-15:50	Discussion	
15:50-16:20	Pneumococcal conjugate vaccines: overview- (infant and adults) 40 min	Ron Dagan, Soroka Medical Center, Beer Sheva
16:20-16:40	Discussion	
16:40-17:00	Break	
17:00-17:30	Meningococcal vaccines (including the MenA-conjugate experience) 40 min	Brian Greenwood, UK
17:30-17:50	Discussion	
17:50-18:30	Special lecture: The population biology of bacterial pathogens and its importance for vaccination strategies	Richard Moxon, Oxford University
18:30-18:50	Discussion	

	TUESDAY 31 MAY 2016	Theme Coordinator : Mark Miller (Bethesda)
	SESSION 8.2 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (2)	Chairperson: Bernard Fritzell , Bordeaux
09:00-09:40	Influenza biology, new vaccines and vaccination strategies for different age groups	Kathy Neuzil, CVD, Baltimore
09:40-10:00	Discussion	
10:00-10:30	Success and challenges with Rotavirus and Norovirus vaccines	Umesh Parashar CDC
10:30-10:50	Discussion	
10:50-11:10	Break	
11:10-11:40	Understanding vaccine responses in the elderly	Richard Aspinall, Anglia Ruskin University, UK
11:40-12:00	Other issues with vaccination in the elderly	Keipp Talbot (Vanderbilt University,)
12:00-12:30	Common Discussion	
12:30-13:30	Lunch	
13:30-15:45	Small group exercise 4: Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness	organized by Kari Johansen, ECDC and Hanna Nohynek
	Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome Group 1 Rota Mark Miller Group 2 Rota Alan Shaw Group 3 HPV Hanna Nohynek Group 4 HPV Edwin Asturias and Kari Johansen Group 5 Influenza Brad Gessner and Keipp Talbot Group 6 Malaria Brian Greenwood	
15:45-16:25	History of Vaccines and Vaccination	Stanley Plotkin, University of Pennsylvania
16:25-16:45	Discussion	
17:00	Soccer game North vs South of the World	
18:45	Introducing the ADVAC alumni network	Fondation Mérieux

		Theme Coordinator : Edwin Asturias
	WEDNESDAY 1 JUNE 2016	
	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES	Chairpersons: Alan Shaw, CDC Foundation ,Atlanta
	1. Vaccination and pregnancy	
08:45-09:30	Scientific basis, main issues and applications	Janet Englund, Children's Hospital and Regional Medical Center, Seattle
09:30-09:50	Discussion	
	2. Vaccination in early life	
09:50-10:20	Advantages and limitations	Claire-Anne Siegrist, University of Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
	3. Vaccination schedules	
11:00-11:30	Past, present and future – is there some rationale?	Edwin Asturias (Children's Hospital Colorado)
11:30-11:50	Discussion	
	Special lecture	
11:50-12:20	The challenge of malaria vaccines and of their potential introduction	Vasee Moorthy , WHO
12:20-12:40	Discussion	
12:40-16:00	Parallel working group sessions (with sandwich lunch)	
	1.Opportunities and challenges for assessing new vaccines in Developing Countries	Orin Levine (BMGF) and Pauline Beattie (EDCTP)
	2.National decision-making for immunization programmes	Rana Hajjeh, CDC, and Philippe Duclos ,WHO and Carine Dochez (NESI)
	3.Clinical vaccinology: patients' problem solving	Claire-Anne Siegrist and Alessandro Diana (UNIGE)
	4. New approaches towards vaccination e-registries	Kari Johansen (ECDC)
16:00-16:20	Break	
	Special lecture	
16:20-17:10	THE 10th PLOTKIN LECTURE: Therapeutic Vaccines	David Weiner, Professor of Pathology and Laboratory Medicine University of Pennsylvania Perelman School of Medicine
17:10-17:40	Discussion	
18:00	Departure to Château de Menthon visit and special reception	

		Theme Coordinator : Edwin Asturias
	THURSDAY 2 JUNE 2016	
		Chairperson: Edwin Asturias
09:00-09:40	Vaccination in immune-compromised individuals, including HIV positive patients	Claire-Anne Siegrist , University of Geneva
09:40-10:00	Discussion	
	<u>Special lectures: New vaccines</u>	
10:00-10:30	HPV vaccines	Margaret Stanley , Cambridge University
10:30-10:50	Discussion	
10:50-11:10	Break	
11:10-11:40	CMV vaccines in development	Stanley Plotkin , University of Pennsylvania
11:40-12:00	Discussion	
12:00-12:30	Prospects for dengue vaccines	Hal Margolis , CDC
12:30-12:50	Discussion	
12:50-13:45	Buffet Lunch	
13:45-14:25	Progress with RSV vaccines: how new technologies can change viral vaccine development	Barney Graham (NIH)
14:25-14:45	Discussion	
14:45-15:15	HIV vaccines	Brigitte Autran , INSERM, France
15:15-15:30	Discussion	
	<u>Elimination or Eradication strategies?</u>	
15:30-16:15	Polio, focusing on new strategies Measles and rubella	Ananda Bandyopadhyay, Bill & Melinda Gates Foundation - 45min
16:15-16:40	General discussion	Stanley Plotkin
17:00	CME credits Diploma ceremony The educational quality of the course will be certified by Prof. Claire-Anne Siegrist and Dr Hanna Nohynek (CME related issues)	Stanley Plotkin, Paul Henri Lambert and Christophe Longuet

	FRIDAY 3 JUNE 2016	Thematic supervisor : Edwin Asturias
	SESSION 10: FACING THE MEDIA	Chairperson: Edwin Asturias
08:45-13:00	Interactive session	Deborah Hall , Broadcaster and media affairs consultant, London,
	Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups Lunch	(organized by Edwin Asturias)
14:30	Closure of the Course	